Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates.

Kaushik A, Ammerman NC, Lee J, Martins O, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.02623-18. doi: 10.1128/AAC.02623-18. [Epub ahead of print]

PMID:
30642943
2.

Inhibition mechanism of L,D-transpeptidase 5 in presence of the β-lactams using ONIOM method.

Tolufashe GF, Sabe VT, Ibeji CU, Lawal MM, Govender T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B.

J Mol Graph Model. 2019 Mar;87:204-210. doi: 10.1016/j.jmgm.2018.11.009. Epub 2018 Nov 28.

PMID:
30554066
3.

The catalytic role of water in the binding site of l,d-transpeptidase 2 within acylation mechanism: A QM/MM (ONIOM) modelling.

Ibeji CU, Tolufashe GF, Ntombela T, Govender T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B.

Tuberculosis (Edinb). 2018 Dec;113:222-230. doi: 10.1016/j.tube.2018.10.005. Epub 2018 Oct 19.

PMID:
30514506
4.

Structure and function of L,D- and D,D-transpeptidase family enzymes from Mycobacterium tuberculosis.

Tolufashe GF, Sabe VT, Ibeji CU, Ntombela T, Govender T, Maguire GEM, Kruger HG, Lamichhane G, Honarparvar B.

Curr Med Chem. 2018 Dec 3. doi: 10.2174/0929867326666181203150231. [Epub ahead of print]

PMID:
30501595
5.

Going green - treatment outcome and safety profile of chronic central serous chorioretinopathy treated with subthreshold green laser.

Khatri A, Pradhan E, Singh S, Rijal R, Khatri BK, Lamichhane G, Kharel M.

Clin Ophthalmol. 2018 Oct 5;12:1963-1971. doi: 10.2147/OPTH.S180663. eCollection 2018.

6.

Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities.

Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G.

Front Microbiol. 2018 Sep 25;9:2273. doi: 10.3389/fmicb.2018.02273. eCollection 2018. Review.

7.

Have we realized the full potential of β-lactams for treating drug-resistant TB?

Story-Roller E, Lamichhane G.

IUBMB Life. 2018 Sep;70(9):881-888. doi: 10.1002/iub.1875. Epub 2018 Jun 22. Review.

PMID:
29934998
8.

Molecular insight on the non-covalent interactions between carbapenems and L,D-transpeptidase 2 from Mycobacterium tuberculosis: ONIOM study.

Ntombela T, Fakhar Z, Ibeji CU, Govender T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B.

J Comput Aided Mol Des. 2018 Jun;32(6):687-701. doi: 10.1007/s10822-018-0121-2. Epub 2018 May 29.

PMID:
29845435
9.

Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis.

Schwartz M, Fisher S, Story-Roller E, Lamichhane G, Parrish N.

Microb Drug Resist. 2018 Oct;24(8):1191-1197. doi: 10.1089/mdr.2017.0286. Epub 2018 Jan 25.

PMID:
29368988
10.

Assessment of visual morbidity amongst diabetic retinopathy at tertiary eye care center, Nepal: a cross-sectional descriptive study.

Pandey A, Lamichhane G, Khanal R, Rai SKC, Bhari AM, Borroni D, Gautam N.

BMC Ophthalmol. 2017 Dec 28;17(1):263. doi: 10.1186/s12886-017-0656-3.

11.

Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.

Kumar P, Chauhan V, Silva JRA, Lameira J, d'Andrea FB, Li SG, Ginell SL, Freundlich JS, Alves CN, Bailey S, Cohen KA, Lamichhane G.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00866-17. doi: 10.1128/AAC.00866-17. Print 2017 Oct.

12.

Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.

Azzali E, Machado D, Kaushik A, Vacondio F, Flisi S, Cabassi CS, Lamichhane G, Viveiros M, Costantino G, Pieroni M.

J Med Chem. 2017 Aug 24;60(16):7108-7122. doi: 10.1021/acs.jmedchem.7b00793. Epub 2017 Aug 10.

PMID:
28749666
13.

Prevalence of Diastolic Dysfunction in Type 2 Diabetes Mellitus.

Yadava SK, Dolma N, Lamichhane G, Poudel N, Barakoti M, Karki DB.

Kathmandu Univ Med J (KUMJ). 2017 Jul-Sept.;15(59):212-216.

PMID:
30353895
14.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

15.

LdtMav2, a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems.

Mattoo R, Lloyd EP, Kaushik A, Kumar P, Brunelle JL, Townsend CA, Lamichhane G.

Future Microbiol. 2017 Jun;12:595-607. doi: 10.2217/fmb-2016-0208. Epub 2017 May 30.

16.

Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem.

Bianchet MA, Pan YH, Basta LAB, Saavedra H, Lloyd EP, Kumar P, Mattoo R, Townsend CA, Lamichhane G.

BMC Biochem. 2017 May 25;18(1):8. doi: 10.1186/s12858-017-0082-4.

17.

Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics.

Fakhar Z, Govender T, Maguire GEM, Lamichhane G, Walker RC, Kruger HG, Honarparvar B.

Mol Biosyst. 2017 Jun 1;13(6):1223-1234. doi: 10.1039/c7mb00110j. Epub 2017 May 8.

PMID:
28480928
18.

Retrospective study on outcome of macular hole surgery.

Singh S, Byanju R, Pradhan S, Lamichhane G.

Nepal J Ophthalmol. 2016 Jul;8(16):139-143. doi: 10.3126/nepjoph.v8i2.17002.

PMID:
28478467
19.

Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.

Njire M, Wang N, Wang B, Tan Y, Cai X, Liu Y, Mugweru J, Guo J, Hameed HMA, Tan S, Liu J, Yew WW, Nuermberger E, Lamichhane G, Liu J, Zhang T.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00070-17. doi: 10.1128/AAC.00070-17. Print 2017 Jul.

20.

Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.

Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C, Parrish N, Lamichhane G.

Future Microbiol. 2017 May;12:473-480. doi: 10.2217/fmb-2016-0234. Epub 2017 Feb 16.

21.

Drug resistance mechanisms and novel drug targets for tuberculosis therapy.

Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T.

J Genet Genomics. 2017 Jan 20;44(1):21-37. doi: 10.1016/j.jgg.2016.10.002. Epub 2016 Oct 11. Review.

PMID:
28117224
22.

Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase.

Dey RJ, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, Kumar P, Guo H, Lamichhane G, Sintim HO, Bishai WR.

Nat Chem Biol. 2017 Feb;13(2):210-217. doi: 10.1038/nchembio.2254. Epub 2016 Dec 12.

PMID:
28106876
23.

Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Kumar P, Kaushik A, Bell DT, Chauhan V, Xia F, Stevens RL, Lamichhane G.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02234-16. doi: 10.1128/AAC.02234-16. Print 2017 Mar.

24.

Non-classical transpeptidases yield insight into new antibacterials.

Kumar P, Kaushik A, Lloyd EP, Li SG, Mattoo R, Ammerman NC, Bell DT, Perryman AL, Zandi TA, Ekins S, Ginell SL, Townsend CA, Freundlich JS, Lamichhane G.

Nat Chem Biol. 2017 Jan;13(1):54-61. doi: 10.1038/nchembio.2237. Epub 2016 Nov 7.

25.

Carbapenems against Mycobacterium tuberculosis: a review of the evidence.

Jaganath D, Lamichhane G, Shah M.

Int J Tuberc Lung Dis. 2016 Nov;20(11):1436-1447. Review.

PMID:
27776583
26.

REMap: Operon map of M. tuberculosis based on RNA sequence data.

Pelly S, Winglee K, Xia FF, Stevens RL, Bishai WR, Lamichhane G.

Tuberculosis (Edinb). 2016 Jul;99:70-80. doi: 10.1016/j.tube.2016.04.010. Epub 2016 Apr 29.

27.

An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria.

Kaushik A, Heuer AM, Bell DT, Culhane JC, Ebner DC, Parrish N, Ippoliti JT, Lamichhane G.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3572-6. doi: 10.1016/j.bmcl.2016.06.019. Epub 2016 Jun 9.

28.

Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Makafe GG, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire MM, Cai X, Liu T, Wang B, Pang W, Tan S, Zhang B, Yew WW, Lamichhane G, Guo J, Zhang T.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6. doi: 10.1128/AAC.00152-16. Print 2016 May.

29.

A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.

Fakhar Z, Naiker S, Alves CN, Govender T, Maguire GE, Lameira J, Lamichhane G, Kruger HG, Honarparvar B.

J Biomol Struct Dyn. 2016 Nov;34(11):2399-417. doi: 10.1080/07391102.2015.1117397. Epub 2016 Apr 4.

PMID:
26612108
30.

Loss of a Functionally and Structurally Distinct ld-Transpeptidase, LdtMt5, Compromises Cell Wall Integrity in Mycobacterium tuberculosis.

Brammer Basta LA, Ghosh A, Pan Y, Jakoncic J, Lloyd EP, Townsend CA, Lamichhane G, Bianchet MA.

J Biol Chem. 2015 Oct 16;290(42):25670-85. doi: 10.1074/jbc.M115.660753. Epub 2015 Aug 24.

31.

Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Kaushik A, Makkar N, Pandey P, Parrish N, Singh U, Lamichhane G.

Antimicrob Agents Chemother. 2015 Oct;59(10):6561-7. doi: 10.1128/AAC.01158-15. Epub 2015 Aug 10.

32.

Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment.

Alyahya SA, Nolan ST, Smith CM, Bishai WR, Sadoff J, Lamichhane G.

PLoS One. 2015 May 21;10(5):e0127907. doi: 10.1371/journal.pone.0127907. eCollection 2015.

33.

Targeting the cell wall of Mycobacterium tuberculosis: a molecular modeling investigation of the interaction of imipenem and meropenem with L,D-transpeptidase 2.

Silva JR, Bishai WR, Govender T, Lamichhane G, Maguire GE, Kruger HG, Lameira J, Alves CN.

J Biomol Struct Dyn. 2016;34(2):304-17. doi: 10.1080/07391102.2015.1029000. Epub 2015 Jul 24.

PMID:
25762064
34.

Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development.

Moraes GL, Gomes GC, Monteiro de Sousa PR, Alves CN, Govender T, Kruger HG, Maguire GE, Lamichhane G, Lameira J.

Tuberculosis (Edinb). 2015 Mar;95(2):95-111. doi: 10.1016/j.tube.2015.01.006. Epub 2015 Jan 29. Review.

35.

Systems biology-based identification of Mycobacterium tuberculosis persistence genes in mouse lungs.

Dutta NK, Bandyopadhyay N, Veeramani B, Lamichhane G, Karakousis PC, Bader JS.

MBio. 2014 Feb 18;5(1). pii: e01066-13. doi: 10.1128/mBio.01066-13.

36.

Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams.

Schoonmaker MK, Bishai WR, Lamichhane G.

J Bacteriol. 2014 Apr;196(7):1394-402. doi: 10.1128/JB.01396-13. Epub 2014 Jan 24.

37.

Central retinal arterial occlusion (CRAO) after phacoemulsification-a rare complication.

Lamichhane G, Gautam P.

Nepal J Ophthalmol. 2013 Jul-Dec;5(2):281-3. doi: 10.3126/nepjoph.v5i2.8746.

PMID:
24172572
38.

Definition and annotation of (myco)bacterial non-coding RNA.

Lamichhane G, Arnvig KB, McDonough KA.

Tuberculosis (Edinb). 2013 Jan;93(1):26-9. doi: 10.1016/j.tube.2012.11.010. Epub 2013 Jan 4.

PMID:
23291152
39.

Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2.

Erdemli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA.

Structure. 2012 Dec 5;20(12):2103-15. doi: 10.1016/j.str.2012.09.016. Epub 2012 Oct 25.

40.

Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.

Sarker M, Talcott C, Madrid P, Chopra S, Bunin BA, Lamichhane G, Freundlich JS, Ekins S.

Pharm Res. 2012 Aug;29(8):2115-27. doi: 10.1007/s11095-012-0741-5. Epub 2012 Apr 4.

41.

A screen for non-coding RNA in Mycobacterium tuberculosis reveals a cAMP-responsive RNA that is expressed during infection.

Pelly S, Bishai WR, Lamichhane G.

Gene. 2012 May 25;500(1):85-92. doi: 10.1016/j.gene.2012.03.044. Epub 2012 Mar 15.

42.

Mycobacterium tuberculosis response to stress from reactive oxygen and nitrogen species.

Lamichhane G.

Front Microbiol. 2011 Aug 27;2:176. doi: 10.3389/fmicb.2011.00176. eCollection 2011. No abstract available.

43.

Essential metabolites of Mycobacterium tuberculosis and their mimics.

Lamichhane G, Freundlich JS, Ekins S, Wickramaratne N, Nolan ST, Bishai WR.

MBio. 2011 Feb 1;2(1):e00301-10. doi: 10.1128/mBio.00301-10.

44.

Copper resistance is essential for virulence of Mycobacterium tuberculosis.

Wolschendorf F, Ackart D, Shrestha TB, Hascall-Dove L, Nolan S, Lamichhane G, Wang Y, Bossmann SH, Basaraba RJ, Niederweis M.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1621-6. doi: 10.1073/pnas.1009261108. Epub 2011 Jan 4.

45.

Ocular manifestations in HIV/AIDS cases in Nepal.

Lamichhane G, Shah DN, Sharma S, Chaudhary M.

Nepal J Ophthalmol. 2010 Jan-Jun;2(1):45-50.

PMID:
21141327
46.

Novel targets in M. tuberculosis: search for new drugs.

Lamichhane G.

Trends Mol Med. 2011 Jan;17(1):25-33. doi: 10.1016/j.molmed.2010.10.004. Epub 2010 Nov 9. Review.

PMID:
21071272
47.

Protective efficacy of BCG overexpressing an L,D-transpeptidase against M. tuberculosis infection.

Nolan ST, Lamichhane G.

PLoS One. 2010 Oct 29;5(10):e13773. doi: 10.1371/journal.pone.0013773.

48.

The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models.

Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR.

PLoS One. 2010 Apr 21;5(4):e10289. doi: 10.1371/journal.pone.0010289.

49.

Genetic requirements for the survival of tubercle bacilli in primates.

Dutta NK, Mehra S, Didier PJ, Roy CJ, Doyle LA, Alvarez X, Ratterree M, Be NA, Lamichhane G, Jain SK, Lacey MR, Lackner AA, Kaushal D.

J Infect Dis. 2010 Jun 1;201(11):1743-52. doi: 10.1086/652497.

50.

The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin.

Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G.

Nat Med. 2010 Apr;16(4):466-9. doi: 10.1038/nm.2120. Epub 2010 Mar 21.

Supplemental Content

Loading ...
Support Center